Biocryst Pharmaceuticals Advances Second Generation Oral Plasma Kallikrein Inhibitors For Hereditary Angioedema Into Preclinical Development

Published: Dec 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) attacks.

Help employers find you! Check out all the jobs and post your resume.

Back to news